Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.48 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 2/20 | 0.41 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2648600 | 0.93 | GCK (0.47) | GCKFFAR2PDE5ACCR4KCNH2 | |
| SCHEMBL2647572 | 0.90 | GCK (0.46) | GCKPDE5A | |
| SCHEMBL2647846 | 0.89 | GCK (0.54) | GCKFFAR2PDE5A | |
| SCHEMBL2648137 | 0.88 | LTC4S (0.52) | GCK | |
| SCHEMBL2649633 | 0.86 | GCK (0.46) | GCKFFAR2KCNH2 | |
| SCHEMBL6607782 | 0.85 | GCK (0.45) | GCKFFAR2KCNH2 | |
| SCHEMBL2647663 | 0.85 | GCK (0.62) | GCKFFAR2KCNH2 | |
| SCHEMBL2654541 | 0.84 | LTC4S (0.48) | GCK | |
| SCHEMBL2658012 | 0.83 | FFAR2 (0.60) | GCKFFAR2KCNH2 | |
| SCHEMBL2647498 | 0.83 | GCK (0.50) | GCKFFAR2PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282611-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | claimed |
| EP-1282611-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | claimed |
| US-6384220-B2 | ANTIDIABETIC AGENTS INCREASING THE EXPRESSION OF GLUCOKINASE (GK) TO IMPROVE GLUCOSE TOLERANCE; INCREASE IN GLUCOSE EXPOSURE COUPLED THROUGH GK IN BETA-CELLS TO INCREASE INSULIN SECRETION AND IN HEPATOCYTES TO INCREASE GLYCOGEN DEPOSITION | HOFFMANN-LA ROCHE INC. | 2002-05-07 | — | — | US | claimed |
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | HOFFMANN-LA ROCHE INC. | 2002-01-03 | — | — | US | claimed |
| WO-2001085706-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | claimed |
| EP-1282611-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | disclosed |
| EP-1282611-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | disclosed |
| US-6384220-B2 | ANTIDIABETIC AGENTS INCREASING THE EXPRESSION OF GLUCOKINASE (GK) TO IMPROVE GLUCOSE TOLERANCE; INCREASE IN GLUCOSE EXPOSURE COUPLED THROUGH GK IN BETA-CELLS TO INCREASE INSULIN SECRETION AND IN HEPATOCYTES TO INCREASE GLYCOGEN DEPOSITION | HOFFMANN-LA ROCHE INC. | 2002-05-07 | — | — | US | disclosed |
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | HOFFMANN-LA ROCHE INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001085706-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | GCKR, GCK, PDXK | GCK 2/4885FFAR2 940/4885PDE5A 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.